Efficacy and safety of single-dose zoledronic acid for osteoporosis in frail elderly women: a randomized clinical trial
Susan L Greenspan, Subashan Perera, Mary Anne Ferchak, David A Nace, Neil M Resnick, Susan L Greenspan, Subashan Perera, Mary Anne Ferchak, David A Nace, Neil M Resnick
Abstract
Importance: Eighty-five percent of institutionalized elderly people have osteoporosis and bone fracture rates 8 to 9 times higher than rates observed among community-dwelling elderly people. Nevertheless, most of these persons are left untreated and are excluded from pivotal osteoporosis trials.
Objective: To determine the efficacy and safety of zoledronic acid to treat osteoporosis in frail elderly women in long-term care facilities.
Design, setting, and participants: We conducted a 2-year, randomized, placebo-controlled, double-blinded study from December 2007 through March 2012. Included were 181 women 65 or older with osteoporosis, including those with cognitive impairment, immobility, and multimorbidity, who were living in nursing homes and assisted-living facilities.
Interventions: One 5-mg dose of zoledronic acid or placebo intravenously and daily calcium and vitamin D supplementation.
Main outcomes and measures: Hip and spine bone mineral density (BMD) at 12 and 24 months and adverse events.
Results: There were no baseline differences in mean (SE) age (85.4 [0.6] years), BMD, or functional or cognitive status, but the treatment group included more participants with frailty, falls history, diabetes, and anticonvulsant medication use. Values for BMD were available for 87% of participants at 12 months and 73% at 24 months. Mean (SE) BMD changes were greater in the treatment group: 3.2 (0.7) and 3.9 (0.7) percentage-point differences in the total hip at 12 and 24 months, respectively (P < .01 for both comparisons), and 1.8 (0.7) and 3.6 (0.7) percentage-point differences at the spine (P < .01); adjusted analyses were similar. The treatment and placebo groups' fracture rates were 20% and 16%, respectively (OR, 1.30; 95% CI, 0.61-2.78); mortality rates were 16% and 13% (OR, 1.24; 95% CI, 0.54-2.86). Groups did not differ in the proportion of single fallers (28% vs 24%; OR, 1.24; 95% CI, 0.64-2.42; P = .52), but more participants in the treatment group had multiple falls (49% vs 35%; OR, 1.83; 95% CI, 1.01-3.33; P = .047); however, this difference was no longer significant when adjusted for baseline frailty.
Conclusions and relevance: In this group of frail elderly women with osteoporosis, 1 dose of zoledronic acid improved BMD over 2 years. The clinical importance of nonsignificant increases in fracture and mortality rates in the treatment group needs further study. Since it is not known whether such therapy reduces the risk of fracture in this cohort, any change in nursing home practice must await results of larger trials powered to assess fracture rates.
Trial registration: clinicaltrials.gov Identifier: NCT00558012.
Figures
![Figure 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4843134/bin/nihms775909f1.jpg)
![Figure 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4843134/bin/nihms775909f2.jpg)
Figure 3
Mean ± SE change in…
Figure 3
Mean ± SE change in biochemical markers of bone turnover including CTX (nmol/L…
- Osteoporosis treatment and fracture outcomes.Lindsay R. Lindsay R. JAMA Intern Med. 2015 Jun;175(6):921-2. doi: 10.1001/jamainternmed.2015.0757. JAMA Intern Med. 2015. PMID: 25866943 No abstract available.
- Dosing Strategies of Bone-Targeting Agents.Hutton B, Mazzarello S, Clemons M. Hutton B, et al. JAMA Intern Med. 2015 Nov;175(11):1864-5. doi: 10.1001/jamainternmed.2015.4789. JAMA Intern Med. 2015. PMID: 26524744 No abstract available.
- Dosing Strategies of Bone-Targeting Agents.Uzoigwe CE. Uzoigwe CE. JAMA Intern Med. 2015 Nov;175(11):1865. doi: 10.1001/jamainternmed.2015.4796. JAMA Intern Med. 2015. PMID: 26524745 No abstract available.
- Dosing Strategies of Bone-Targeting Agents-Reply.Greenspan SL, Perera S, Resnick NM. Greenspan SL, et al. JAMA Intern Med. 2015 Nov;175(11):1865-6. doi: 10.1001/jamainternmed.2015.4799. JAMA Intern Med. 2015. PMID: 26524746 Free PMC article. No abstract available.
- Efficacy and safety of a once-yearly intravenous zoledronic acid 5 mg for fracture prevention in elderly postmenopausal women with osteoporosis aged 75 and older.Boonen S, Black DM, Colón-Emeric CS, Eastell R, Magaziner JS, Eriksen EF, Mesenbrink P, Haentjens P, Lyles KW. Boonen S, et al. J Am Geriatr Soc. 2010 Feb;58(2):292-9. doi: 10.1111/j.1532-5415.2009.02673.x. Epub 2010 Jan 8. J Am Geriatr Soc. 2010. PMID: 20070415 Free PMC article.
- Once-yearly zoledronic acid in older men compared with women with recent hip fracture.Boonen S, Orwoll E, Magaziner J, Colón-Emeric CS, Adachi JD, Bucci-Rechtweg C, Haentjens P, Kaufman JM, Rizzoli R, Vanderschueren D, Claessens F, Sermon A, Witvrouw R, Milisen K, Su G, Lyles KW; HORIZON Recurrent Fracture Trial. Boonen S, et al. J Am Geriatr Soc. 2011 Nov;59(11):2084-90. doi: 10.1111/j.1532-5415.2011.03666.x. Epub 2011 Oct 21. J Am Geriatr Soc. 2011. PMID: 22091563 Clinical Trial.
- Intravenous Zoledronic Acid 5 mg on Bone Turnover Markers and Bone Mineral Density in East China Subjects with Newly Diagnosed Osteoporosis: A 24-month Clinical Study.Liang BC, Shi ZY, Wang B, Wu P, Kong LC, Yao JL, Li CW, Shi XL. Liang BC, et al. Orthop Surg. 2017 Feb;9(1):103-109. doi: 10.1111/os.12307. Epub 2017 Mar 9. Orthop Surg. 2017. PMID: 28276638 Free PMC article. Clinical Trial.
- Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR; HORIZON Pivotal Fracture Trial. Black DM, et al. N Engl J Med. 2007 May 3;356(18):1809-22. doi: 10.1056/NEJMoa067312. N Engl J Med. 2007. PMID: 17476007 Clinical Trial.
- Review of the cardiovascular safety of zoledronic acid and other bisphosphonates for the treatment of osteoporosis.John Camm A. John Camm A. Clin Ther. 2010 Mar;32(3):426-36. doi: 10.1016/j.clinthera.2010.03.014. Clin Ther. 2010. PMID: 20399982 Review.
- Diabetes Mellitus is Associated with Poor Bone Microarchitecture in Older Adults Residing in Long-Term Care Facilities.Haeri NS, Kotlarczyk MP, Perera S, Greenspan SL. Haeri NS, et al. J Osteoporos. 2022 Dec 19;2022:2522014. doi: 10.1155/2022/2522014. eCollection 2022. J Osteoporos. 2022. PMID: 36578470 Free PMC article.
- Fractures reduction with osteoporotic treatments in patients over 75-year-old: A systematic review and meta-analysis.Guillaumin M, Poirson B, Gerazime A, Puyraveau M, Tannou T, Mauny F, Toussirot É. Guillaumin M, et al. Front Aging. 2022 Nov 2;3:845886. doi: 10.3389/fragi.2022.845886. eCollection 2022. Front Aging. 2022. PMID: 36404990 Free PMC article.
- Does Zoledronic Acid Improve Appendicular Lean Mass in Older Women with Osteoporosis? A Sub-Analysis of a Randomized Clinical Trial.Haeri NS, Perera S, Greenspan SL. Haeri NS, et al. J Frailty Aging. 2022;11(4):420-425. doi: 10.14283/jfa.2022.54. J Frailty Aging. 2022. PMID: 36346729 Free PMC article. Clinical Trial.
- Controversies in Osteoporosis Treatment of Nursing Home Residents.Niznik JD, Gilliam MA, Colón-Emeric C, Thorpe CT, Lund JL, Berry SD, Hanson LC. Niznik JD, et al. J Am Med Dir Assoc. 2022 Dec;23(12):1928-1934. doi: 10.1016/j.jamda.2022.09.013. Epub 2022 Nov 3. J Am Med Dir Assoc. 2022. PMID: 36335990 Review.
- Treatment thresholds and minimal clinically important effect sizes of antiosteoporotic medication-Survey among physicians and lay persons in Germany.van der Keylen P, Zeschick N, Schlenz AR, Kühlein T. van der Keylen P, et al. PLoS One. 2022 Aug 11;17(8):e0272985. doi: 10.1371/journal.pone.0272985. eCollection 2022. PLoS One. 2022. PMID: 35951613 Free PMC article.
- Randomized Controlled Trial
- Research Support, N.I.H., Extramural
- Aged, 80 and over
- Bone Density / drug effects
- Bone Density Conservation Agents / administration & dosage*
- Bone Density Conservation Agents / adverse effects
- Bone Remodeling / drug effects
- Diphosphonates / administration & dosage*
- Diphosphonates / adverse effects
- Double-Blind Method
- Female
- Humans
- Imidazoles / administration & dosage*
- Imidazoles / adverse effects
- Infusions, Intravenous
- Osteoporosis / drug therapy*
- Zoledronic Acid
- Bone Density Conservation Agents
- Diphosphonates
- Imidazoles
- Zoledronic Acid
- ClinicalTrials.gov/NCT00558012
- Full Text Sources
- Other Literature Sources
- Medical
![Figure 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4843134/bin/nihms775909f3.jpg)
Source: PubMed